Preliminary in-vivo evaluation of [68Ga]Ga-FAPI-46 in a fibroblast activation protein–negative breast cancer model
Authors:
- 26 February 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
Abstract
Objectives: Fibroblast activation protein (FAP), which is abundantly expressed in cancer-associated fibroblasts, is an attractive target for tumour imaging and therapy. [ 68 Ga]Ga-FAPI-46, a gallium-68-labelled FAP inhibitor, has demonstrated favourable pharmacokinetics for PET. This study evaluated the radiolabelling efficiency, stability, and biodistribution of [ 68 Ga]Ga-FAPI-46 in a breast cancer mouse model using MCF-7 cell line, which is known to lack FAP expression. Methods: [ 68 Ga]Ga-FAPI-46 was radiolabeled directly from FAPI-46 using 68 Ga in acetate buffer and analysed for radiochemical purity (RCP) by radio-TLC. Stability at room temperature was assessed up to 5 h post-radiolabeling. Biodistribution studies were conducted in female BALB/c nude mice with MCF-7 tumours. Organ uptake was determined 1 h after injection and expressed as a percentage of injected dose per gramme of tissue (%ID/g). A comparative study between [ 68 Ga]Ga-FAPI-46 and free 68 Ga was also performed. Results: [ 68 Ga]Ga-FAPI-46 consistently achieved high RCP values (>95%, maximum 99.1%) and remained stable for up to 5 h without added radioprotectant. At 1 h, [ 68 Ga]Ga-FAPI-46 showed higher uptake in kidneys (4.15%ID/g), heart (3.59%ID/g), and liver (1.70%ID/g), and low uptake in muscle (0.31%ID/g) and bone (0.57%ID/g). Mean tumour uptake was low (0.92%ID/g), consistent with the FAP-negative status of MCF-7 cells. In contrast, free 68 Ga showed a non-specific distribution in blood (29.13%ID/g), lungs (18.50%ID/g), and bone (13.37%ID/g). Conclusion: [ 68 Ga]Ga-FAPI-46 showed efficient radiolabelling with high RCP and short-term stability. Its low accumulation in FAP-negative tumours supports tracer selectivity and provides a baseline for comparative studies in FAP-expressing tumour models.Keywords
This publication has 38 references indexed in Scilit:
- Optimization and scale-up of [68Ga]Ga-FAPI-46 production on a Modular-Lab PharmTracer platform for clinical applicationNuclear Medicine and Biology, 2024
- Unlocking the crucial role of cancer-associated fibroblasts in tumor metastasis: Mechanisms and therapeutic prospectsJournal of Advanced Research, 2024
- Development of novel radiolabeled antibody-conjugated graphene quantum dots for targeted in vivo breast cancer imaging and biodistribution studiesArabian Journal of Chemistry, 2024
- Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation libraryChem, 2022
- Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2022
- Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblastsActa Pharmaceutica Sinica B, 2021
- 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validationRadiotherapy and Oncology, 2021
- 68Ga-FAPI-PET/CT in patients with various gynecological malignanciesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancerHuman Pathology, 2013
- 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitterNuclear Medicine and Biology, 2012